Filana Therapeutics, Inc. (FLNA)
| Market Cap | 30.70M -82.8% |
| Revenue (ttm) | n/a |
| Net Income | -42.28M |
| EPS | -0.88 |
| Shares Out | 48.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 313,552 |
| Open | 0.6440 |
| Previous Close | 0.6541 |
| Day's Range | 0.6156 - 0.6533 |
| 52-Week Range | 0.6156 - 4.0100 |
| Beta | -0.66 |
| Analysts | Buy |
| Price Target | 6.50 (+922.82%) |
| Est. Earnings | Nov 11, 2026 |
About FLNA
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer’s disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for FLNA stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 922.82% from the latest price.
News
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-...
Filana can proceed with study as hold lifted, says Lucid Capital
Lucid Capital analyst Elemer Piros reiterates a Buy rating on Filana Therapeutics (FLNA) with an $8 price target after the company said the FDA has lifted the clinical hold on…
Filana Therapeutics announces U.S. FDA lifted clinical hold on simufilam
Filana Therapeutics (FLNA) announced that the U.S. Food and Drug Administration, FDA, has lifted the clinical hold on the Company’s investigational new drug, IND, application, enabling Filana to initi...
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recr...
Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Filana Therapeutics Earnings release: Q2 2026
Filana Therapeutics released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Filana Therapeutics Quarterly report: Q2 2026
Filana Therapeutics has published its Q2 2026 quarterly earnings report on July 29, 2026.
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for T...
Filana Therapeutics Slides: Corporate presentation
Filana Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 29, 2026.
Filana Therapeutics Transcript: AGM 2026
The meeting addressed ongoing efforts to resolve the FDA clinical hold on the TSC epilepsy program, introduced new executive team members, and approved all voting proposals, including director reelections and incentive plan amendments. No questions were raised by stockholders.
Filana Therapeutics resumed with Buy at Maxim on rebranding, strategic pivot
As previously reported, Maxim resumed coverage of Filana Therapeutics (FLNA) with a Buy rating and $5 price target The firm is positive on the company’s rebranding and strategic pivot toward…
Filana Therapeutics resumed with a Buy at Maxim
Maxim resumed coverage of Filana Therapeutics (FLNA) with a Buy rating and $5 price target
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tu...
Filana Therapeutics Earnings release: Q1 2026
Filana Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Filana Therapeutics Quarterly report: Q1 2026
Filana Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Filana Therapeutics Slides: Corporate presentation
Filana Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tu...
Filana Therapeutics Proxy statement: Proxy filing
Filana Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Filana Therapeutics publishes simufilam preclinical data
Filana Therapeutics (FLNA) announced publication in Epilepsia of preclinical data showing that simufilam attenuated seizure progression in a well-accepted mouse model of severe TSC-related epilepsy. T...
Filana Therapeutics management to meet with Maxim
Meeting to be held on March 24-25 hosted by Maxim.
Filana Therapeutics reports Q4 EPS (26c) vs. (57c) last year
“At Filana Therapeutics (FLNA), our name reflects our deep commitment to science and to patients affected by diseases tied to filamin A dysregulation, including TSC-related epilepsy. We are driven by…
Filana Therapeutics sees 1H26 net cash use in operations $14M-$17M
The Company estimates net cash use in operations for first half of 2026 in a range from $14 to $17 million, plus a payment of a $31.25 million estimated loss…
Filana Therapeutics Annual report: Q4 2025
Filana Therapeutics has published its Q4 2025 annual report on March 12, 2026.
Filana Therapeutics Earnings release: Q4 2025
Filana Therapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Filana Therapeutics Slides: Investor presentation
Filana Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.